There are more than 50 drug regimens available to treat metastatic breast cancer but little guidance on the best order to deliver them, according to a study published in JCO Clinical Cancer Informatics.
Treatment timing may affect overall survival in women with estrogen receptor (ER)—positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (mBC), according to study results published in JCO Clinical Cancer Informatics.
There are more than 50 drug regimens available to treat mBC, but little guidance from the National Comprehensive Cancer Network on the best order to deliver them to achieve optimal results, noted the study authors, who investigated the interrelationship of prior treatment time, previous lines of therapy, and survival following treatment with paclitaxel.
Their retrospective cohort study incorporated data from Flatiron Health on 234 women with ER—positive, HER2-negative mBC with distant metastasis in 2014, chosen to ensure consistent guideline-based treatment options and 5-year follow-up, and a primary cancer diagnosis that occurred after 1980. The primary outcome of overall survival (OS) was defined as, “time from initiation of drug of interest in the metastatic setting to death as a result of any cause.”
The median (interquartile range [IQR]) age at primary diagnosis was 57 (IQR, 48-66) years, 69% of the women were white, and 63% had recurrent mBC. They were followed for a maximum of 70 months. Treatment duration lasted from the first date therapy was administered to death or 30 days after their final treatment, while progression-free survival (PFS) was based on the first date of therapy through date of disease progression.
There were several important findings. The median survival was 20 (IQR, 8-53) months, and there was a negative correlation between OS and when paclitaxel was administered in the course of treatment. There was a 16% greater hazard of death (HR, 1.16; 95% CI, 1.05-1.29) following receipt of paclitaxel for every year on treatment before receiving the taxane therapy.
This increased hazard of death remained elevated through several measures of prior treatments:
In addition, results show increased HRs for patients who had metastatic disease diagnosed in both 2013 and 2015:
In addition, the patients shown to have longer survivals after their initial diagnosis, “had prolonged duration of endocrine therapy prior to paclitaxel and other chemotherapies.”
“Prior time on treatment should be considered as a stratifying factor in randomized trials and a confounding factor when examining survival in observational data,” concluded the authors. “This visualization approach can enhance our capacity to harness the power of patient-level data to better understand treatment patterns and their influence on survival outcomes.”
To make progress in optimizing sequential treatment for patients with cancer, they suggest adjustments to data analyzation in future studies: randomizing study participants by time on previous treatment and accounting for confounding by prior treatment duration.
Also, because more than 90% of trials among patients with ER-positive, HER2-negative mBC do not produce meaningful improvements in OS and PFS, the authors are calling for future studies to address the effects of pre- and posttrial treatments on these patients.
Reference
Rocque GB, Gilbert A, Williams CP, et al. Prior treatment time affects survival outcomes in metastatic breast cancer. JCO Clin Cancer Inform. 2020;4:500-513. doi:10.1200/CCI.20.00008
Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women
May 13th 2024A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Social Equity, Strong Health Care Systems Can Improve Advanced Breast Cancer Outcomes Globally
May 6th 2024Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More